Fauchi: Early 'Corona' treatments are a bridge to vaccine

The director of the National Institute of Allergy and Infectious Diseases in the United States, Anthony Fauci, said that the monoclonal antibodies that prevent the spread of the Corona virus in the body are among the promising strategies to avoid serious diseases as a result of infection with “Covid-19” before vaccinations are reached.

And Bloomberg quoted Fauchi as saying that treatments that depend on antibodies and other blood products from recovering patients, and antiviral drugs, are being examined as an early treatment, and the goal is to protect patients from serious lung damage that needs to be given to drugs such as "remdesivir" and Dexamethasone.

Fauchi told the Journal of the American Medical Association in an interview the day before yesterday: "We are now very focused on treating early infection or preventing infection or both, and this is the bridge to the vaccine."

Fauchi explained that immunization against the Corona virus could begin in the United States in November or December, yet it will likely take until the third quarter of 2021 at least, to protect a sufficient number of Americans from the epidemic virus to eliminate its threat significantly.

Fauci said that 100 million doses of the vaccine will likely be produced by December, and all six companies that supply the United States are expected to have produced 700 million doses by next April.

Follow our latest local and sports news, and the latest political and economic developments via Google news